Blinatumomab for leukemia that returns after a stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older and have a type of leukemia called B-cell acute lymphoblastic leukemia (B-ALL).
- You have had a stem cell transplant (from yourself or a donor) and the leukemia has returned after the transplant.
- Before the transplant, your leukemia was considered high-risk, hard-to-treat (refractory), or had relapsed.
- At 3 or 6 months after the transplant, tests show a very small number of leukemia cells (called MRD) but not a full relapse.
- You are generally well enough to be treated (ECOG score 0-2) and your liver, kidneys, and other organs are working adequately.
- You do not have serious active infections, uncontrolled graft-versus-host disease (GVHD), or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This study tests a drug called blinatumomab as a maintenance treatment to help keep your leukemia in remission after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have already received a transplant.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.